Maris JM, Guo C, Blake D, White PS, Hogarty MD, Thompson PM, et al. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol. 2001;36(1):32–6.
Article
CAS
PubMed
Google Scholar
Spitz R, Hero B, Ernestus K, Berthold F. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol. 2003;41(1):30–5.
Article
PubMed
Google Scholar
Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, et al. Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. Br J Cancer. 2015;112(2):290–5.
Article
CAS
PubMed
Google Scholar
Koyama H, Zhuang T, Light JE, Kolla V, Higashi M, McGrady PW, et al. Mechanisms of CHD5 Inactivation in neuroblastomas. Clin Cancer Res. 2012;18(6):1588–97.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang HW, Chen YZ, Takita J, Soeda E, Piao HY, Hayashi Y. Genomic structure and mutational analysis of the human KIF1B gene which is homozygously deleted in neuroblastoma at chromosome 1p36.2. Oncogene. 2001;20(36):5075–83.
Article
CAS
PubMed
Google Scholar
Wang W, Zhong Q, Teng L, Bhatnagar N, Sharma B, Zhang X, et al. Mutations that disrupt PHOXB interaction with the neuronal calcium sensor HPCAL1 impede cellular differentiation in neuroblastoma. Oncogene. 2014;33(25):3316–24.
Article
CAS
PubMed
Google Scholar
Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930–5.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mosse YP, Laudenslager M, Khazi D, Carlisle AJ, Winter CL, Rappaport E, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet. 2004;75(4):727–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45(3):279–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lasorsa VA, Formicola D, Pignataro P, Cimmino F, Calabrese FM, Mora J, et al. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. Oncotarget. 2016;7(16):21840–52.
Article
PubMed
PubMed Central
Google Scholar
Oldridge DA, Wood AC, Weichert-Leahey N, Crimmins I, Sussman R, Winter C, et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature. 2015;528(7582):418–21.
Article
CAS
PubMed
PubMed Central
Google Scholar
De Wilde B, Beckers A, Lindner S, Kristina A, De Preter K, Depuydt P, et al. The mutational landscape of. Oncotarget. 2018;9(9):8334–49.
Article
PubMed
Google Scholar
Sanmartín E, Yáñez Y, Fornés-Ferrer V, Zugaza JL, Cañete A, Castel V, et al. TIAM1 variants improve clinical outcome in neuroblastoma. Oncotarget. 2017;8(28):45286–97.
Article
PubMed
PubMed Central
Google Scholar
Powers JT, Tsanov KM, Pearson DS, Roels F, Spina CS, Ebright R, et al. Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma. Nature. 2016;535(7611):246–51.
Article
CAS
PubMed
PubMed Central
Google Scholar
Romani M, Scaruffi P, Casciano I, Mazzocco K, Lo Cunsolo C, Cavazzana A, et al. Stage-independent expression and genetic analysis of tp73 in neuroblastoma. Int J Cancer. 1999;84(4):365–9.
Article
CAS
PubMed
Google Scholar
Carén H, Ejeskär K, Fransson S, Hesson L, Latif F, Sjöberg RM, et al. A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation. Mol Cancer. 2005;4(1):10.
Article
PubMed
PubMed Central
CAS
Google Scholar
Maris JM, Kyemba SM, Rebbeck TR, White PS, Sulman EP, Jensen SJ, et al. Molecular genetic analysis of familial neuroblastoma. Eur J Cancer. 1997;33(12):1923–8.
Article
CAS
PubMed
Google Scholar
Li S, Fell SM, Surova O, Smedler E, Wallis K, Chen ZX, et al. The 1p36 Tumor Suppressor KIF 1Bβ Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis. Dev Cell. 2016;36(2):164–78.
Article
CAS
PubMed
Google Scholar
Choo Z, Koh RY, Wallis K, Koh TJ, Kuick CH, Sobrado V, et al. XAF1 promotes neuroblastoma tumor suppression and is required for KIF1Bβ-mediated apoptosis. Oncotarget. 2016;7(23):34229–39.
Article
PubMed
PubMed Central
Google Scholar
Chen ZX, Wallis K, Fell SM, Sobrado VR, Hemmer MC, Ramsköld D, et al. RNA helicase A is a downstream mediator of KIF1Bβ tumor-suppressor function in neuroblastoma. Cancer Discov. 2014;4(4):434–51.
Article
CAS
PubMed
Google Scholar
Fransson S, Martinsson T, Ejeskär K. Neuroblastoma tumors with favorable and unfavorable outcomes: Significant differences in mRNA expression of genes mapped at 1p36.2. Genes Chromosomes Cancer. 2007;46(1):45–52.
Article
CAS
PubMed
Google Scholar
Yeh IT, Lenci RE, Qin Y, Buddavarapu K, Ligon AH, Leteurtre E, et al. A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum Genet. 2008;124(3):279–85.
Article
CAS
PubMed
Google Scholar
Guzmán C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS ONE. 2014;9(3): e92444.
Article
PubMed
PubMed Central
CAS
Google Scholar
Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature. 2011;476(7359):163–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Henrich KO, Schwab M, Westermann F. 1p36 tumor suppression–a matter of dosage? Cancer Res. 2012;72(23):6079–88.
Article
CAS
PubMed
Google Scholar
Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, et al. CHD5 is a tumor suppressor at human 1p36. Cell. 2007;128(3):459–75.
Article
CAS
PubMed
Google Scholar
Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008;22(7):884–93.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nagai M, Ichimiya S, Ozaki T, Seki N, Mihara M, Furuta S, et al. Identification of the full-length KIAA0591 gene encoding a novel kinesin-related protein which is mapped to the neuroblastoma suppressor gene locus at 1p36.2. Int J Oncol. 2000;16(5):907–16.
CAS
PubMed
Google Scholar
Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res. 2008;68(8):2551–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Okawa ER, Gotoh T, Manne J, Igarashi J, Fujita T, Silverman KA, et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene. 2008;27(6):803–10.
Article
CAS
PubMed
Google Scholar
Gorringe KL, Choong DY, Williams LH, Ramakrishna M, Sridhar A, Qiu W, et al. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia. 2008;10(11):1253–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Virden RA, Thiele CJ, Liu Z. Characterization of critical domains within the tumor suppressor CASZ1 required for transcriptional regulation and growth suppression. Mol Cell Biol. 2012;32(8):1518–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu Z, Lam N, Wang E, Virden RA, Pawel B, Attiyeh EF, et al. Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma. Oncogene. 2017;36(1):97–109.
Article
CAS
PubMed
Google Scholar
Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene. 2003;22(7):1002–11.
Article
CAS
PubMed
Google Scholar
Garcia I, Mayol G, Rodríguez E, Suñol M, Gershon TR, Ríos J, et al. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer. 2010;9:277.
Article
PubMed
PubMed Central
CAS
Google Scholar
Paul S, Kuo A, Schalch T, Vogel H, Joshua-Tor L, McCombie WR, et al. Chd5 requires PHD-mediated histone 3 binding for tumor suppression. Cell Rep. 2013;3(1):92–102.
Article
CAS
PubMed
PubMed Central
Google Scholar
Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011;21(1):47–55.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ng D, Yang XR, Tucker MA, Goldstein AM. Mutation screening of CHD5 in melanoma-prone families linked to 1p36 revealed no deleterious coding or splice site changes. BMC Res Notes. 2008;1:86.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lang J, Tobias ES, Mackie R. Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma. Br J Dermatol. 2011;164(5):1010–6.
Article
CAS
PubMed
Google Scholar
Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, et al. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015;47(8):872–7.
Article
CAS
PubMed
Google Scholar
Kolla V, Zhuang T, Higashi M, Naraparaju K, Brodeur GM. Role of CHD5 in human cancers: 10 years later. Cancer Res. 2014;74(3):652–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Munirajan AK, Ando K, Mukai A, Takahashi M, Suenaga Y, Ohira M, et al. KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. J Biol Chem. 2008;283(36):24426–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Welander J, Andreasson A, Juhlin CC, Wiseman RW, Bäckdahl M, Höög A, et al. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2014;99(7):E1352–60.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ma X, Li M, Tong A, Wang F, Cui Y, Zhang X, et al. Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study. Front Endocrinol (Lausanne). 2020;11: 574662.
Article
Google Scholar
Seo SH, Kim JH, Kim MJ, Cho SI, Kim SJ, Kang H, et al. Whole Exome Sequencing Identifies Novel Genetic Alterations in Patients with Pheochromocytoma/Paraganglioma. Endocrinol Metab (Seoul). 2020;35(4):909–17.
Article
CAS
Google Scholar
Evenepoel L, Helaers R, Vroonen L, Aydin S, Hamoir M, Maiter D, et al. KIF1B and NF1 are the most frequently mutated genes in paraganglioma and pheochromocytoma tumors. Endocr Relat Cancer. 2017;24(8):L57–61.
Pillai S, Gopalan V, Lo CY, Liew V, Smith RA, Lam AK. Silent genetic alterations identified by targeted next-generation sequencing in pheochromocytoma/paraganglioma: A clinicopathological correlations. Exp Mol Pathol. 2017;102(1):41–6.
Article
CAS
PubMed
Google Scholar
Capasso M, Diskin SJ, Totaro F, Longo L, De Mariano M, Russo R, et al. Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis. 2013;34(3):605–11.
Article
CAS
PubMed
Google Scholar
Cimmino F, Avitabile M, Diskin SJ, Vaksman Z, Pignataro P, Formicola D, et al. Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor. Int J Cancer. 2018;143(11):2828–37.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shi J, Yu Y, Jin Y, Lu J, Zhang J, Wang H, et al. Functional Polymorphisms in. J Cancer. 2019;10(10):2153–60.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chan SH, Chew W, Ishak NDB, Lim WK, Li ST, Tan SH, et al. Clinical relevance of screening checklists for detecting cancer predisposition syndromes in Asian childhood tumours. NPJ Genom Med. 2018;3:30.
Article
PubMed
PubMed Central
CAS
Google Scholar
Latorre V, Diskin SJ, Diamond MA, Zhang H, Hakonarson H, Maris JM, et al. Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans. Cancer Epidemiol Biomarkers Prev. 2012;21(4):658–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang R, Zou Y, Zhu J, Zeng X, Yang T, Wang F, et al. The Association between GWAS-identified BARD1 Gene SNPs and Neuroblastoma Susceptibility in a Southern Chinese Population. Int J Med Sci. 2016;13(2):133–8.
Article
CAS
PubMed
PubMed Central
Google Scholar